Regeneron Pharmaceuticals, Inc.

Type: Public
On the web: http://www.regeneron.com
Employees: 1,704
Employee growth: 22.2%

Regeneron is fighting some serious enemies. Regeneron Pharmaceuticals develops protein-based drugs used to battle a variety of diseases and conditions, including cancer, inflammatory ailments, and eye diseases. The biotechnology company's first commercialized product is ARCALYST, a treatment for rare inflammatory diseases including Muckle-Wells Syndrome. Regeneron collaborates with Sanofi to develop candidate aflibercept (VEGF Trap) as a possible treatment for cancerous tumors. It is also developing aflibercept with Bayer HealthCare to treat eye diseases using intraocular delivery, with EYLEA approved in the US (2011) and Australia (2012) as a treatment of neovascular age-related macular degeneration (wet AMD).

Key numbers for fiscal year ending December, 2011:
Sales: $445.8M
One year growth: (2.9%)
Net income: ($221.8)M

Officers:
Chairman: P. Roy Vagelos
President, CEO, and Director: Leonard S. Schleifer
SVP Finance and Administration, CFO, Assistant Secretary, and Treasurer: Murray A. Goldberg

Competitors:
Amgen
Novartis
Roche Holding